en · de · es · fr · pt
tirzepatide-notes.peptides8425.com › Wiki › Analytical Characterization And Storage Stability — Background and Details

Analytical Characterization And Storage Stability — Background and Details

By Editorial Desk · published 2025-09-02 · last reviewed 2025-09-29 · Wiki

Everything below concerns fatty diacid. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Updated 2025-09-29. Numbers and descriptions here follow the published literature rather than marketing material.

Analytical Characterization and Storage Stability

Common degradation routes include hydrolysis of labile amide bonds, deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation. Aggregates can form during freeze-thaw cycling, at elevated pH, or when peptide concentration is high. Each route produces characteristic chromatographic or mass shifts that are tracked during stability studies. Whether a given minor impurity alters biological activity is often an open question, and specification limits are typically set on identity and purity rather than on functional data for trace species.

Lyophilized material is generally held at -20 degrees Celsius or lower, desiccated and protected from light, where it remains stable for extended periods. Reconstituted or ready-to-use solution is usually kept at 2 to 8 degrees Celsius with minimal agitation. Repeated freeze-thaw cycles should be avoided because they promote aggregation and reduce the soluble monomer fraction. Shipment of frozen solid commonly uses dry ice, while refrigerated liquid moves with validated cold packs. Stability beyond documented periods is not established.

Characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity and related-substance profiling, with ultraviolet detection near 214 nanometers. Mass spectrometry confirms molecular mass and reveals modifications such as oxidation or deamidation. Peptide mapping after enzymatic digestion verifies the amino acid sequence, while amino acid analysis supplies compositional data. Circular dichroism and infrared spectroscopy are used to assess secondary structure, particularly the alpha-helical content that influences aggregation behavior in solution.

储存处理与检测方法

溶解操作一般使用注射用水或适宜的水性缓冲液,必要时加入少量助溶剂以改善溶解速度,但应避免剧烈涡旋振荡,因为剪切力可能促进聚集。配制后的溶液在冷藏条件下的稳定时间通常短于固体形态,具体时限取决于浓度、缓冲体系与容器材质。是否加入防腐成分,则取决于用途是否为多次取样。

定量分析的主流方法是反相高效液相色谱联用紫外或质谱检测,利用肽在疏水固定相上的保留行为确定纯度与含量。对于生物基质中的浓度测定,常采用液相色谱串联质谱,并配合固相萃取或蛋白沉淀进行样品前处理。免疫分析法也可使用,但可能受到结构相关肽的交叉反应干扰。

Tirzepatide at a glance

PropertyValueNotes
AppearanceWhite to off-white powderLyophilized solid form
Purity assay95 percent or greater by RP-HPLCTypical research-grade specification
Storage temperature2 to 8 degrees CelsiusFormulated solution, do not freeze
Common analytical methodLC-MS with peptide mappingIdentity and impurity confirmation
Primary degradation routesDeamidation, oxidation, aggregationTracked in stability programs

Analytical Characterization and Storage

Analytical characterization of tirzepatide typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) for purity assessment and peptide mapping. Mass spectrometry, often coupled with electrospray ionization, confirms molecular weight and sequence integrity. Amino acid analysis and capillary electrophoresis may also be used to detect impurities or degradation products. These methods are essential for batch release and stability studies.

Storage recommendations for tirzepatide generally specify refrigeration at 2–8 °C to maintain stability. The peptide should be protected from light and kept in its original packaging to prevent aggregation or adsorption. Freezing is not recommended because freeze-thaw cycles can cause aggregation or precipitation. Once dispensed, storage conditions and in-use periods follow product-specific labeling, which may allow room temperature storage for a limited time.

Degradation pathways for tirzepatide include deamidation, oxidation, and aggregation, which are common for therapeutic peptides. These processes can be monitored by size-exclusion chromatography (SEC) for aggregates and ion-exchange chromatography for charge variants. Forced degradation studies under acidic, basic, oxidative, and thermal stress help identify potential impurities. The exact stability profile depends on formulation, concentration, and container-closure system.

Related pages on this site

Tirzepatide Pharmacology and Development History

Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.

The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.

Background and Molecular Development

Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.

Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.

The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.

Background And Receptor Pharmacology

Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.

Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.

Background from the literature

=== Serotonin turnover === Studies have shown that benzoctamine increases level of serotonin. Scientists confirmed these results and proposed that the method of action was inhibition of serotonin uptake since the drug also blocked the serotonin depleting action of extra-neuronal monoamine transporters (EMT). This would lead to increased stimulation of serotonin receptors through a negative feed back mechanism, eventually decreasing serotonin out put. However, the study points out that other studies have shown that drugs combined with EMT cause a lowering of body temperature that in fact results in a decrease in serotonin turnover. This means that body temperature effects cannot be ruled out.

=== 2011 Scottish Parliament election === In January 2011, Galloway launched his campaign in preparation of the May Scottish Parliament election, announcing that he would standing in the Glasgow region. Respect and Solidarity formed an alliance for the election, with Galloway being their top candidate in Glasgow. On the regional ballot, Respect-Solidarity polled 6,972 list votes (3.3%), failing to elect any candidates, though did finish ahead of the Liberal Democrats who lost their seat.

The classical approach tends to suffer from poor yields as HMF continues to react in aqueous acid, forming levulinic acid. As sugar is not generally soluble in solvents other than water, the development of high-yielding reactions has been slow and difficult; hence while furfural has been produced on a large scale since the 1920s, HMF was not produced on a commercial scale until over 90 years later. The first production plant coming online in 2013. Numerous synthetic technologies have been developed, including the use of ionic liquids, microdroplets, continuous liquid-liquid extraction, reactive distillation, and solid acid catalysts to either remove the HMF before it reacts further or to otherwise promote its formation and inhibit its decomposition.

Sources: en.wikipedia.org

Reference notes

=== Sexual stimulation and arousal === The clitoris has an abundance of nerve endings, and is the human female's most erogenous part of the body. When sexually stimulated, it may incite sexual arousal, which may result from mental stimulation (sexual fantasy), activity with a sexual partner, or masturbation, and can lead to orgasm. The most effective sexual stimulation of this organ is usually manually or orally, which is often referred to as direct clitoral stimulation; in cases involving sexual penetration, these activities may also be referred to as additional or assisted clitoral stimulation. Direct stimulation involves physical stimulation to the external anatomy of the clitoris – glans, hood, and shaft. Stimulation of the labia minora, due to it being connected with the glans and hood, may have the same effect as direct clitoral stimulation. Though these areas may also receive indirect physical stimulation during sexual activity, such as when in friction with the labia majora, indirect clitoral stimulation is more commonly attributed to penile-vaginal penetration. Penile-anal penetration may also indirectly stimulate the clitoris by the shared sensory nerves (especially the pudendal nerve, which gives off the inferior anal nerves and divides into two terminal branches: the perineal nerve and the dorsal nerve of the clitoris).

IPT combined with pharmacotherapy was more effective in preventing relapse than pharmacotherapy alone, number needed to treat = 7.63. Couples therapy is sometimes recommended for people with depression. The goal of this therapy is to support the person with depression and emphasize the mutually supportive angle often associated with intimate partners and relationships, and provide mutual support for both partners and help manage any interpersonal changes in their relationship. Psychoanalysis, a school of thought founded by Sigmund Freud that emphasizes the resolution of unconscious mental conflicts, is used by its practitioners to treat clients presenting with major depression. A more widely practiced technique, called psychodynamic psychotherapy, is loosely based on psychoanalysis and has an additional social and interpersonal focus. In a meta-analysis of three controlled trials, psychodynamic psychotherapy was found to be as effective as medication for mild to moderate depression.

=== Other === Pozzolan-lime cements are mixtures of ground pozzolan and lime. These are the cements the Romans used, and are present in surviving Roman structures like the Pantheon in Rome. They develop strength slowly, but their ultimate strength can be very high. The hydration products that produce strength are essentially the same as those in Portland cement. Slag-lime cements—ground granulated blast-furnace slag—are not hydraulic on their own, but are "activated" by addition of alkalis, most economically using lime. They are similar to pozzolan lime cements in their properties. Only granulated slag (i.e., water-quenched, glassy slag) is effective as a cement component. Supersulfated cements contain about 80% ground granulated blast furnace slag, 15% gypsum or anhydrite and a little Portland clinker or lime as an activator. They produce strength by formation of ettringite, with strength growth similar to a slow Portland cement. They exhibit good resistance to aggressive agents, including sulfate. Calcium aluminate cements are hydraulic cements made primarily from limestone and bauxite. The active ingredients are monocalcium aluminate CaAl2O4 (CaO · Al2O3 or CA in cement chemist notation, CCN) and mayenite Ca12Al14O33 (12 CaO · 7 Al2O3, or C12A7 in CCN). Strength forms by hydration to calcium aluminate hydrates. They are well-adapted for use in refractory (high-temperature resistant) concretes, e.g., for furnace linings. Calcium sulfoaluminate cements are made from clinkers that include ye'elimite (Ca4(AlO2)6SO4 or C4A3S in Cement chemist's notation) as a primary phase.

Sources: en.wikipedia.org

Frequently asked questions

How is peptide purity normally measured?

Reversed-phase high-performance liquid chromatography is the standard approach, separating the main peak from related impurities. Ultraviolet detection near 214 nanometers captures the peptide backbone. Mass spectrometry is then used alongside chromatography to confirm identity and detect covalent modifications.

Why does freeze-thaw cycling matter?

Cycling between frozen and liquid states concentrates the peptide at ice interfaces, which favors non-covalent association. The resulting aggregates may be invisible to simple assays yet alter recovery and apparent potency. Limiting the number of cycles and aliquoting before storage are common mitigations.

Is the compound sensitive to light?

Tryptophan and methionine side chains can undergo photo-induced oxidation, so amber glass or opaque packaging is typical. The effect is gradual and depends on wavelength and exposure time. Light protection is usually specified for both solid and solution forms.

固体粉末应如何存放?

建议在低温、避光、干燥环境中密封保存,常见条件为 2 至 8 摄氏度,长期存放可置于更低温度。应避免反复冻融,并尽量减少容器开启次数。

Network